Delivery Order SPE2DR25D1007-SPE2DR26FY8EV
- Not listed
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $5,085.29 by the Defense Logistics Agency on August 13, 2025, for the supply of Zepbound 15 mg/0.5 mL pens. This firm fixed-price, competitively awarded contract represents a child order under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The delivery order...
- The Defense Logistics Agency awarded a $22,463.06 delivery order to AmerisourceBergen Drug Corp for Zepbound 15 mg/0.5 mL pens on November 17, 2025, with an ultimate completion date of November 18, 2025. This non-set-aside contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor,...
- This delivery order, issued May 27, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, provides for the supply of Zepbound 5 mg/0.5 mL pens at a firm fixed price ceiling value of $2,270.15. The order is to be completed by May 28, 2025, with performance conducted at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This non-set-aside award was competitively procured and represents a delivery order issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $2,287.74 delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pens. This competitively awarded, firm fixed-price order is scheduled for completion by October 28, 2025, with performance to be executed at AmerisourceBergen's Corporate Office facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the contractor's demonstrated capability to compete successfully in...
- The Defense Logistics Agency awarded a $3,679.86 delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injections. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on May 16, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens with a ceiling value of $2,104.73. This is a firm fixed-price delivery order with an ultimate completion date of May 19, 2025, and represents a non-set-aside competitive award. The order will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. As a child contract, this delivery order falls under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $5,467.68 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 5, 2025, for the supply of Zepbound 5 mg/0.5 mL pens. This competitively awarded contract, which is not set-aside, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical valued at $999,999,999.00 through December 2026. The ultimate completion date for this order is November 6, 2025, with performance...
- AmerisourceBergen Drug Corp received a delivery order from the Defense Logistics Agency (DLA) on September 2, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injections, with a contract ceiling value of $7,625.80. The order is structured as a firm fixed-price delivery order with an ultimate completion date of September 3, 2025, and represents a non-set-aside competitive award. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,233.41 to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 mL pens on July 31, 2025, with completion scheduled for August 1, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,118.42 for Zepbound 15 mg/0.5 mL pen injectors on November 10, 2025, with an ultimate completion date of November 12, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award represents a child order under a larger contract vehicle supporting federal...
- SPE2DR25D1007Indefinite Delivery Contract
- SPE2DR25D1007-SPE2DR26FY8EVDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order from the Defense Logistics Agency (DLA) on November 18, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pens valued at $1,570.16. This competitively awarded, firm fixed-price delivery order is scheduled for completion by November 19, 2025, with performance occurring at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation and represents a child order under a larger contract vehicle. This delivery order derives from AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. The contract enables AmerisourceBergen to supply brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. Zepbound, a GLP-1 receptor agonist used for weight management, aligns with the military healthcare system's pharmaceutical procurement needs and demonstrates the company's role as a critical vendor for federal medical supply chains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 11/18/25 |